DUBLIN--(BUSINESS WIRE)--The "Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global fiducial markers market is valued at USD 95 million in 2019 and expected to reach USD 123 million by 2025, at a CAGR of 4.5% from 2019 to 2025.
The growth of the fiducial markers market is mainly attributed to factors such as the growing incidences of cancer, growing adoption of radiotherapy procedures, improving reimbursement scenario, and rising awareness on radiotherapy. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities - especially in emerging markets, which are expected to witness the highest growth. However, a dearth of skilled professionals, high marker costs, and a lack of adequate healthcare infrastructure are expected to limit market growth during the forecast period.
The metal-based markers segment commanded the largest share of the fiducial markers market in 2018.
Based on the product, the fiducial markers market is segmented into metal-based, polymer-based, and other fiducial markers. The metal-based markers segment is further subsegmented into pure gold markers, gold combination markers, and other metal-based markers (tungsten, platinum, and nitinol, among others). The metal-based markers segment commanded the largest share of the fiducial markers market in 2018. The growing adoption of IGRT for the treatment of prostate cancer and the rising incidences of prostate cancer are expected to fuel the adoption of metal-based fiducial markers in the near future.
The CT/CBCT segment held the major share of the global market in 2018.
In terms of modality, the fiducial markers market is classified into CT/CBCT, MRI, ultrasound, and radiotherapy. The CT/CBCT segment held the major share of the global market in 2018. It is anticipated to reach USD 54.0 million by 2025. CBCT is preferred for prostate and lung cancer indications, as it can effectively detect changes in the position of cancer tumors. This is supporting the growth of the CT/CBCT segment.
North America is projected to hold the largest share of the market.
The fiducial markers market, by region, is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the market, by region, during the forecast period. This is attributed to the expansion of the target patient population, favorable reimbursement scenario, greater accessibility to radiotherapy procedures, and the presence of major players in this region.
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by top players in the fiducial markers market
- Product Development/Innovation: Detailed insights on upcoming trends, R&D activities, and product launches in the fiducial markers market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the fiducial markers market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of leading market players.
Key Topics Covered:
1.1 Objectives of the Study
1.2 Market Definition
2 Research Methodology
2.1 Research Data
2.2 Market Size Estimation
2.3 Market Breakdown & Data Triangulation
2.4 Assumptions for the Study
2.5 Research Limitations
3 Executive Summary
4 Premium Insights
4.1 Fiducial Markers: Market Overview
4.2 Fiducial Markers Market, By Product & Region, 2019
4.3 Market, By Modality, 2019-2025
4.4 Market, By Cancer Type, 2019 Vs. 2025
4.5 Market Share, By End User, 2019 Vs. 2025
4.6 Geographic Snapshot of the Market, 2019
5 Market Overview
5.2 Market Dynamics
6 Market, By Product
6.2 Metal-Based Markers
6.3 Polymer-Based Markers
6.4 Other Fiducial Markers
7 Market, By Modality
8 Market, By Cancer Type
8.2 Prostate Cancer
8.3 Lung Cancer
8.4 Gastric Cancer
8.5 Breast Cancer
8.6 Other Cancers
9 Market, By End User
9.2 Hospitals & Outpatient Facilities
9.3 Independent Radiotherapy Centers
9.4 Cancer Research Centers
10 Market, By Region
10.2 North America
10.4 Asia Pacific
10.5 Latin America
10.6 Middle East & Africa
11 Competitive Landscape
11.2 Market Share Analysis
11.3 Competitive Scenario
11.4 Competitive Leadership Mapping
12 Company Profiles
12.1 CIVCO Radiotherapy
12.2 Boston Scientific Corporation
12.3 IZI Medical Products
12.5 Naslund Medical AB
12.7 Best Medical International, Inc.
12.8 Nanovi A/S
12.9 Carbon Medical Technologies
12.10 Eckert & Ziegler
12.11 Innovative Oncology Solutions
12.12 QlRad Inc.
12.13 Stellar Medical
12.16 Other Companies
12.16.1 Varian Medical Systems, Inc.
12.16.2 Beekley Corporation
12.16.3 Innomedicus Ag
12.16.4 Meditronix Corporation
12.16.5 Seedos Ltd
For more information about this report visit https://www.researchandmarkets.com/r/ozjkl7